Case 1: 72-Year-Old Former Smoker with Stage-IIIA NSCLC and PD-L1 of 90%

Developers will now initiate the phase 3 MarsLight-11 trial of IBI363 among patients with immunotherapy-resistant squamous non–small cell lung cancer.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Prior data from the STRESS-LUNG-1 trial introduced emotional distress as a “psycho-biomarker” for immunotherapy efficacy in non–small cell lung cancer.

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.

The drug that the companion diagnostic identifies patients for, zongertinib, received FDA approval for HER2-mutant NSCLC on August 8, 2025.